Monitoring safety of sintilimab in Chinese patients
Treatments studied
Part of Immune system & allergy clinical trials.
This study carefully tracks how safe sintilimab is for people with cancer in real-world care. It may help your care team understand side effects and risks during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old
- Your cancer is confirmed by a tissue or cell test, and you are planning to receive sintilimab
- You can likely live at least 6 months and can do most daily activities (ECOG 0–2 or KPS 60+)
- You have not taken an “immune checkpoint” medicine before
- Your blood, liver, kidney, and thyroid tests must be within allowed ranges
- You must not have certain conditions (like active autoimmune disease, interstitial lung disease, or pregnancy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs for people with advanced non-small cell lung cancer. The drugs aim to help your immune system fight the cancer more effectively.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy to shrink advanced lung cancer that cannot be removed with surgery. The goal is to see if the cancer becomes operable after treatment and to improve outcomes.
This trial tests whether using the immunotherapy drug sintilimab after surgery, guided by a blood test that looks for tiny bits of cancer DNA (MRD), can help keep non-small cell lung cancer from coming back. It is for people who had immunotherapy before surgery and still had some cancer left after the operation.
This trial tests whether adding an immune checkpoint inhibitor (a drug that helps your immune system fight cancer) as maintenance therapy after chemoradiotherapy improves outcomes for people with locally advanced head and neck cancer. It specifically looks at a marker in your blood (CD8Tex cells) to see if you might benefit.
This trial is for people with non-small cell lung cancer who have already had immunotherapy and chemotherapy before surgery, followed by complete removal of the tumor. It tests whether continuing immunotherapy after surgery (adjuvant treatment) can lower the risk of cancer coming back compared to just watching and waiting.
This trial looks at adding sintilimab (an immunotherapy) after surgery for certain stages of esophageal squamous cell cancer. The goal is to lower the chance the cancer comes back after standard treatment.
Hear when a new PD-1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.